Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
US11116839B2 · kind B2 · utility
4Cited by
43References
26Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Aug 2, 2018 |
| Grant date | Sep 14, 2021 |
| Priority date | — |
| Expiry date | May 4, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides methods for reducing lipoprotein(a) (Lp(a)) in patients. The methods of the present invention comprise selecting a patient who exhibits elevated serum Lp(a), and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.